Browse by ▼

Zoetis

  • 3 Stock Picks for Pet Lovers

    By Robert Ciura - June 14, 2013 | Tickers: PETS, PETM, ZTS

    Debate rages on as to whether the U.S. consumer is healthy once again. There’s good reason for this, since the U.S. economy is so heavily dependent on consumer spending. But while consumers often cut back on discretionary items when the economy goes south, there’s been little evidence that consumers have cut back on spending on their pets.

    In fact, just the opposite—the American Pet Products more »

  • Is Concentration Better Than Diversification in Pharma?

    By Nicholas Kitonyi - June 13, 2013 | Tickers: AZN, PFE, ZTS

    Pfizer (NYSE: PFE) recently completed the spin-off of its animal health unit, Zoetis (NYSE: ZTS). The company offered to acquire its stake in Zoetis for a 7% discount, in exchange of all or part of its shareholding. This is subject to an upper limit of 0.9898 shares of Zoetis common stock per share of Pfizer common stock. This spin-off is expected to reflect on Pfizer’s EPS beginning 2014 more »

  • Does Pfizer's Unwinding of Its Stake in Zoetis Offer Value for Either Company's Shareholders?

    By Mike Thiessen - June 5, 2013 | Tickers: MRK, PFE, ZTS

    Pfizer (NYSE: PFE) surprised the investment community with the recent announcement that it would attempt to offload the remainder of its stake in veterinary pharmaceutical firm Zoetis (NYSE: ZTS). At minimum, the transaction would be designed to reduce Pfizer's take in Zoetis to non-majority, non-controlling levels. However, the ultimate goal appears to be the complete liquidation of Pfizer's interest in its former subsidiary. Although many industry observers expected more »

  • In Pets We Trust

    By Grant Hosticka - May 31, 2013 | Tickers: PETS, PETM, ZTS

    Pets are a huge industry that doesn’t receive much attention from investors, and it could be one of the safest during hard economic times.  According to the American Pet Products Association in 2012, $53.33 billion dollars were spent on pets within the U.S. market, and 62% of U.S. households own a pet. I consider pet supplies a non-cynical item. People don’t stop feeding a pet more »

  • Do Major Drug Manufacturers Have Room to Grow?

    By Chris Hodge - May 21, 2013 | Tickers: AZN, LLY, ZTS

    Major drug manufacturers are literally a market sector unto themselves. With valuations that frequently soar into the $50 billion level and beyond, these companies have already grown to incredible proportions. But can they grow further still, or is the best they can do to keep going along a steady path?

    Never underestimate a dark horse

    AstraZeneca (NYSE: AZN) is a Swedish and British company, which automatically puts its epicenter into more »

  • Three Stocks to Profit from Zombie Apocalypse Thinking

    By AnnaLisa Kraft - April 29, 2013 | Tickers: ABBV, KRFT, ZTS

    The rationale behind the popularity of  doomsday zombie scenarios is that the future is so bleak even zombies come as a welcome alternative. That's the theory of author, Doug Rushkoff, whose "Present Shock" details the hurry up world that is traumatizing us.

    One example of his was the Facebook IPO. People expected to make immediate bucks and when they didn't they fled the stock. "When everything happens now more »

  • The Pharma Stock to Focus on in 2013

    By Victor Selva - April 24, 2013 | Tickers: MRK, MWIV, ZTS

    Zoetis (NYSE: ZTS) is an animal health company that used to be one of Pfizer’s business units. It only started trading as an independent company in February 2013, despite being the largest operating firm (in terms of revenue) in the animal health medicine and vaccine sector.

    For the long-term, the business seems pretty well positioned to grow, especially considering the increasing demand from emerging economies. On this occasion, we more »

  • The Pharma Stock to Focus in 2013

    By Victor Selva - April 12, 2013 | Tickers: MRK, PFE, ZTS

    Zoetis (NYSE: ZTS) is an animal health company that used to be one of Pfizer’s (NYSE: PFE) business units. It only started trading as an independent company in February of 2013, despite being the largest operating firm (in terms of revenues) in the animal health medicine and vaccine sector. In the long-term, the business seems pretty well positioned to grow, especially considering the increasing demand of emerging economies. In more »

  • Underpriced IPOs May Have Big Upside

    By Austin Higgins - April 11, 2013 | Tickers: NCLH, PFE, ZTS

    Total initial public offerings have declined during the first quarter from the same time last year. In the first quarter of 2012, there were 42 IPOs. In the same quarter this year, only 31 came out.

    Even with the stock market booming this year, investment banks and venture capitalists have been cautious with offerings. Because of this caution, some of these companies may have been underpriced. As the year goes more »

  • Underpriced IPOs May Have Big Upside

    By Austin Higgins - April 8, 2013 | Tickers: NCLH, PFE, ZTS

    Total initial public offerings have declined during the first quarter from the same time last year. In the first quarter of 2012, there were 42 IPOs. In the same quarter this year, only 31 came out.

    Even with the stock market booming this year, investment banks and venture capitalists have been cautious with offerings. Because of this caution, some of these companies may have been underpriced. As the year goes more »

  • $11 Million Worth of Insiders Sales in This Pet Stock

    By Anh HOANG - April 8, 2013 | Tickers: PETS, PETM, ZTS

    In March, PetSmart (NASDAQ: PETM) insiders, including the chief financial officer, senior vice president of marketing, and senior vice president of of real estate and development, sold more than 177,000 shares of the company at around $62.20, with a total transaction value of more than $11 million.

    From  2009 to 2012, PetSmart has experienced consistent growth in its stock price, rising from $19 per share to more than more »

  • $11 Million Insiders Sales in This Pet Stock

    By Anh HOANG - April 3, 2013 | Tickers: PETS, PETM, ZTS

    In March, insiders including the CFO, Senior VP of Marketing and Senior VP of Real Estate and Development of PetSmart (NASDAQ: PETM) has sold more than 177,000 shares of the company at around $62.2, with a total transaction value of more than $11 million. In the period of 2009 to 2012, PetSmart has experienced a consistent growth in its stock price, from $19 per share to more than more »

  • Will This Successful Spin-off Mean More Spin-offs in the Industry?

    By Mike Thiessen - March 28, 2013 | Tickers: MRK, PFE, SNY, ZTS

    After a wildly successful IPO that raised over $2 billion, and valued the newly-created company at more than $12 billion, pharmaceutical giant Pfizer (NYSE: PFE) retains about 80% of the equity in its former animal drugs division Zoetis (NYSE: ZTS).

    Although Pfizer has not made any formal announcements of its plans for the remaining stake, it is widely expected to unwind a significant portion of its investment during the coming more »

  • Will This Successful Spin-off Mean More Spin-offs in the Industry?

    By Mike Thiessen - March 18, 2013 | Tickers: MRK, PFE, SNY, ZTS

    After a wildly successful IPO that raised over $2 billion and valued the newly-created company at more than $12 billion, pharmaceutical giant Pfizer (NYSE: PFE) retains about 80 percent of the equity in its former animal drugs division Zoetis (NYSE: ZTS). Although Pfizer has not made any formal announcements of its plans for the remaining stake, it is widely expected to unwind a significant portion of its investment during the more »

  • Merck’s Struggles to Replace Singulair Lead to Biosimilars

    By Peter Pham - March 9, 2013 | Tickers: BMY, MRK, PFE, ZTS

    Merck & Co. (NYSE: MRK), the world’s third largest drug maker by sales, is partnering with South Korean Samsung Bioepis, a joint venture that operates as a subsidiary of Samsung Biologics, to develop and market ‘bio-similar’ drugs that act as alternative to the much more expensive biologic drugs. The financial details of the deal weren’t disclosed, but it was revealed that Samsung Bioepis will develop the drugs and would more »

  • This Pet Pharmacy is for Value Investors

    By Anh HOANG - February 26, 2013 | Tickers: PETS, PETM, ZTS

    Are you interested in a business that has been growing its top line and bottom line consistently for the last 10 years? In addition, this business has a quite conservative capital structure, with a lot of cash on hand and no leverage. At the time of writing, the business was trading at single digit EV multiple. It is PetMed Express (NASDAQ: PETS), a pet pharmacy small cap stock.

    Business Snapshot more »

  • A Global Leader in Animal Health - Spinoff Opportunity?

    By Anh HOANG - February 22, 2013 | Tickers: MRK, PFE, ZTS

    Although spin-off situations offered investors compelling investment opportunities most of the time, investors should study each situation quite carefully to determine its own attractiveness. Recently, Pfizer (NYSE: PFE) has sold 86.1 million class A shares in its animal health unit, Zoetis (NYSE: ZTS) in the form of an IPO. After the offering, Pfizer still retains around 82.8% of the economic interest in Zoetis. Let’s dig deeper to more »

  • Three Risks to Consider for This Dow-30 Healthcare Giant

    By Reuben Brewer - February 21, 2013 | Tickers: JNJ, MRK, PFE, ZTS

    Johnson & Johnson (NYSE: JNJ) looks like it's about to turn a corner in its business. Manufacturing quality issues appear to be abating, its new drugs and drug pipeline are both looking strong, and the largest acquisition in its history is ahead of plan. All of this means that the next few years could see notable growth. However, investors should bear in mind three issues that could derail even J more »

  • Are These Spinoffs Better Bets Than Their Parents?

    By AnnaLisa Kraft - February 15, 2013 | Tickers: ABBV, PSX, SHOS, ZTS

    Spinoffs have been a big theme over the last six months as more companies try to maximize shareholder value. Some of these have outperformed their parents. Big cap companies like Pfizer, ConocoPhillips, Sears Holdings, and Abbott Labs all spun off divisions.  Zoetis (NYSE: ZTS), Phillips 66(NYSE: PSX), Sears Hometown and Outlet Stores (NASDAQ: SHOS), and AbbVie (NYSE: ABBV) have done fairly well since their IPOs.

    AbbVie is up 10 more »

  • 'Best Of Breed' Stocks

    By AnnaLisa Kraft - February 14, 2013 | Tickers: MWIV, PETS, PETM, TSCO, ZTS

    How we love our animals! I bet many viewers tuned out the State of the Union Address to watch the Westminister Dog Show. The Puppy Bowl had a strong showing even against the Super Bowl. Some spoil these pets with outrageous presents such as Louis Vuitton carriers, fragrance for dogs at $3,000 a bottle, and $3 million dog collars. Even those of us who would blanch at these gifts more »

  • Page 1 of 2